Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 17/20 | 0.55 |
| ▸ | JAK3 | P52333 | 12/20 | 0.55 |
| ▸ | CDK2 | P24941 | 4/20 | 0.53 |
| ▸ | JAK1 | P23458 | 7/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.53 |
| ▸ | TYK2 | P29597 | 2/20 | 0.53 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.53 |
| ▸ | PLK4 | O00444 | 1/20 | 0.53 |
| ▸ | CIT | O14578 | 1/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.53 |
| ▸ | OPA1 | O60313 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | STK16 | O75716 | 1/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.53 |
| ▸ | MARK3 | P27448 | 1/20 | 0.53 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.53 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.53 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | STAT5A | P42229 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4385539 | 0.86 | JAK2 (0.59) | JAK2JAK3CDK2JAK1HDAC1 | |
| SCHEMBL4385566 | 0.85 | JAK2 (0.51) | JAK2JAK3CDK2JAK1HDAC1 | |
| SCHEMBL4386916 | 0.84 | ACVR1 (0.53) | JAK2JAK3CDK2JAK1HDAC1 | |
| SCHEMBL4380467 | 0.84 | JAK2 (0.77) | JAK2JAK3CDK2JAK1HDAC1 | |
| SCHEMBL4383485 | 0.83 | JAK2 (0.57) | JAK2JAK3CDK2JAK1HDAC1 | |
| SCHEMBL4584376 | 0.83 | JAK2 (0.58) | JAK2JAK3CDK2JAK1HDAC1 | |
| SCHEMBL4473090 | 0.82 | JAK2 (0.63) | JAK2JAK3CDK2JAK1HDAC1 | |
| SCHEMBL4376933 | 0.82 | JAK2 (0.63) | JAK2JAK3CDK2JAK1HDAC1 | |
| SCHEMBL4385543 | 0.82 | JAK2 (0.53) | JAK2JAK3CDK2JAK1HDAC1 | |
| SCHEMBL4384366 | 0.82 | JAK2 (0.60) | JAK2JAK3CDK2JAK1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-8440663-B2 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-1979329-A2 | 4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007089768-A2 | 4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | EXELIXIS, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885CDK2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.